Mallia Therapeutics is developing soluble CD83 (sCD83), a human glycoprotein that stimulates the formation of new hair follicles to promote hair regrowth in patients experiencing hair loss. This topical treatment offers a non-systemic application with a favorable safety profile, addressing the significant impact of hair loss on quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Hair loss significantly impacts quality of life and can lead to anxiety and depression. Current treatments often have systemic side effects or limited efficacy. There is a need for safe and effective topical treatments that stimulate new hair follicle formation.
Solution
Mallia Therapeutics is developing soluble CD83 (sCD83), a human glycoprotein, as a topical treatment to stimulate the formation of new hair follicles and promote hair regrowth. sCD83 works by directly binding to follicular stem cells and inducing an anti-inflammatory micro-milieu. As a human glycoprotein with non-systemic application, sCD83 is expected to have a superior safety profile compared to existing treatments. Preclinical models for androgenetic alopecia and alopecia areata have demonstrated the efficacy of sCD83.
Target Audience
The primary target audience includes individuals experiencing hair loss, specifically those with androgenetic alopecia and alopecia areata, seeking a safe and effective topical treatment option.
Features
- Topical application for targeted delivery to hair follicles
- sCD83, a human glycoprotein, minimizes the risk of systemic toxicity
- Induces an anti-inflammatory micro-milieu to support hair growth
- Directly binds to follicular stem cells to stimulate new hair follicle formation
- Demonstrated efficacy in preclinical models of androgenetic alopecia and alopecia areata